Endocrine Progenitor Cell Differentiation Using Small Molecule Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pancreatic endoderm cells into endocrine progenitor cells are inefficient, limiting the production of fully differentiated beta-cells necessary for treating type I diabetes.
Innovation Solution
A method involving the use of specific small molecules such as TGF-β type I receptor inhibitors, BMP antagonists, adenylate cyclase activators, and nicotinamide, along with gefitinib, JNK inhibitor VIII, and DAPT, to increase the percentage of NGN3/NKX2.2 double positive cells, enhancing the efficiency and homogeneity of endocrine progenitor cell differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional stepwise differentiation protocols are used to generate endocrine progenitor cells from pancreatic endoderm, then the differentiation process can be established, but the percentage of NGN3/NKX2.2 double positive cells remains low and the process is inefficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition of the differentiation medium through the addition of specific small molecules (TGF-β type I receptor inhibitor, BMP antagonist, adenylate cyclase activator, and nicotinamide). These molecular parameters are optimized to enhance the differentiation efficiency from pancreatic endoderm to endocrine progenitor cells, directly increasing the percentage of NGN3/NKX2.2 double positive cells while reducing the time required for the process.
2Stability of the object's composition
If conventional differentiation methods are used, then the process can proceed, but the resulting endocrine progenitor cell population lacks homogeneity and synchronization
Solution Approach 1:
The patent modifies the differentiation parameters by incorporating a specific combination of small molecules that work synergistically to synchronize the differentiation process. The TGF-β type I receptor inhibitor, BMP antagonist, adenylate cyclase activator, and nicotinamide collectively create a controlled chemical environment that promotes uniform differentiation timing and pathway activation, resulting in a more homogeneous and synchronized endocrine progenitor cell population without sacrificing productivity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to differentiation of stem cells into a homogeneous endocrine progenitor cell population suitable for further differentiation into pancreatic beta-cells. The present invention provides methods for obtaining NGN3/NKX2.2 double positive endocrine progenitor cells by exposing precursor cells to a TGF-β type I receptor inhibitor, a BMP antagonist, an adenylate cyclase activator and nicotinamide and/or exposing to the precursor cells to a selection of small molecules.